Skip to main content


Fig. 2 | Molecular Cancer

Fig. 2

From: Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia

Fig. 2

Targeting RAF–MEK–ERK signaling pathway. GTP-bounding RAS recruits and activates RAF, which in turn initiates a cascade of protein phosphorylation starting with MEK. Activated MEK phosphorylates ERK that moves from the cytoplasm to the nucleus where it phosphorylates several transcription factors. Mutational activation of RAF–MEK–ERK cascade contributes to progression of the disease. Selective inhibitors of MEK, e.g. trametinib, cause potent and durable suppression of ERK signaling

Back to article page